These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26931343)

  • 1. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.
    Tamura K; Hashimoto J; Tanabe Y; Kodaira M; Yonemori K; Seto T; Hirai F; Arita S; Toyokawa G; Chen L; Yamamoto H; Kawata T; Lindemann J; Esaki T
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):787-95. PubMed ID: 26931343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in
    Banerji U; Dean EJ; Pérez-Fidalgo JA; Batist G; Bedard PL; You B; Westin SN; Kabos P; Garrett MD; Tall M; Ambrose H; Barrett JC; Carr TH; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Elvin P; Foxley A; Lawrence P; Lindemann JPO; Maudsley R; Pass M; Rowlands V; Rugman P; Schiavon G; Yates J; Schellens JHM
    Clin Cancer Res; 2018 May; 24(9):2050-2059. PubMed ID: 29066505
    [No Abstract]   [Full Text] [Related]  

  • 3. AKT Inhibition in Solid Tumors With AKT1 Mutations.
    Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
    J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363.
    Yates JW; Dudley P; Cheng J; D'Cruz C; Davies BR
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):343-56. PubMed ID: 26092323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with
    Smyth LM; Tamura K; Oliveira M; Ciruelos EM; Mayer IA; Sablin MP; Biganzoli L; Ambrose HJ; Ashton J; Barnicle A; Cashell DD; Corcoran C; de Bruin EC; Foxley A; Hauser J; Lindemann JPO; Maudsley R; McEwen R; Moschetta M; Pass M; Rowlands V; Schiavon G; Banerji U; Scaltriti M; Taylor BS; Chandarlapaty S; Baselga J; Hyman DM
    Clin Cancer Res; 2020 Aug; 26(15):3947-3957. PubMed ID: 32312891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
    Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
    Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
    Dean E; Banerji U; Schellens JHM; Krebs MG; Jimenez B; van Brummelen E; Bailey C; Casson E; Cripps D; Cullberg M; Evans S; Foxley A; Lindemann J; Rugman P; Taylor N; Turner G; Yates J; Lawrence P
    Cancer Chemother Pharmacol; 2018 May; 81(5):873-883. PubMed ID: 29541803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
    Henary H; George GC; Wheler J; Naing A; Piha-Paul S; Fu S; Mistry R; Zinner R; Kurzrock R; Hong DS
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):597-603. PubMed ID: 26210681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Mutant AKT in Cancer.
    Cancer Discov; 2016 Jan; 6(1):OF7. PubMed ID: 26577299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
    Aghajanian C; Bell-McGuinn KM; Burris HA; Siu LL; Stayner LA; Wheler JJ; Hong DS; Kurkjian C; Pant S; Santiago-Walker A; Gauvin JL; Antal JM; Opalinska JB; Morris SR; Infante JR
    Invest New Drugs; 2018 Dec; 36(6):1016-1025. PubMed ID: 29611022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors.
    Doi T; Tamura K; Tanabe Y; Yonemori K; Yoshino T; Fuse N; Kodaira M; Bando H; Noguchi K; Shimamoto T; Ohtsu A
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):409-16. PubMed ID: 26104654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKT1
    John P; Waldt N; Liebich J; Kesseler C; Schnabel S; Angenstein F; Sandalcioglu IE; Scherlach C; Sahm F; Kirches E; Mawrin C
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12780. PubMed ID: 34837233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
    Davies BR; Greenwood H; Dudley P; Crafter C; Yu DH; Zhang J; Li J; Gao B; Ji Q; Maynard J; Ricketts SA; Cross D; Cosulich S; Chresta CC; Page K; Yates J; Lane C; Watson R; Luke R; Ogilvie D; Pass M
    Mol Cancer Ther; 2012 Apr; 11(4):873-87. PubMed ID: 22294718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
    Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
    Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
    Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
    Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
    Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
    Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
    Castaneda C; Meadows KL; Truax R; Morse MA; Kaufmann SH; Petros WP; Zhu Y; Statkevich P; Cutler DL; Hurwitz HI
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):455-63. PubMed ID: 20972873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.